Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
June 17, 2010
Choosing Skin and Eye Disorders, RXi Will Face Well-Worn R&D Paths
The two areas, which have opportunities RXi's CEO called "tremendous" and "significant," have been well worn by rival drug companies making similar bets including Sirnaomics, TransDerm, and Quark Pharmaceuticals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Isis Exec Sees Antisense as Third Major Drug Platform, Says More Work to Be Done
April 19, 2012 / Gene Silencing News - Alnylam, Max Planck Settle Suit Over Tuschl IP
March 17, 2011 / Gene Silencing News - Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News - In Changing RNAi Rx Guidance, Pfizer Becomes Latest Big Pharma to Shift Expectations
November 4, 2010 / Gene Silencing News